Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| PGEN | PRECIGEN, INC. | 2025-10-30 17:42:03 | 4.05 | 0 | 0 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PGEN | 0001356090 | PRECIGEN, INC. | US74017N1054 | 549300XCWNQU35K64G19 | — | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | VA | 20374 SENECA MEADOWS PARKWAY | GERMANTOWN | MD | 20876 | UNITED STATES | US | 301-556-9900 | 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876 | 20374 SENECA MEADOWS PARKWAY, GERMANTOWN, MD, 20876 | INTREXON CORP | Biotechnology | 1998-05-21 | — | 600 | http://precigen.com | 239,800,000 | 297,846,160 | 297,972,920 | Precigen, Inc. (formerly Intrexon Corporation, NASDAQ: PGEN) is an American biotechnology company. Its president and CEO is Helen Sabzevari. Intrexon was founded in 1998, and is headquartered in Germantown, Maryland. With a suite of proprietary and complementary technologies, Intrexon applies engineering to biological systems to enable DNA-based control over the function and output of living cells. | 2025-10-30 14:24:30 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 239,800,000 | 62,500,000 | 35.251 | 295,165,060 | 42,745,370 | 16.9342 |
| 2023 | 177,300,000 | 15,200,000 | 9.3769 | 252,419,690 | 224,977 | 0.0892 |
| 2022 | 162,100,000 | -628,300,000 | -79.4914 | 252,194,713 | 45,262,871 | 21.8733 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Don Lehr | Chief Legal Officer | 2024 | 575,000 | 0 | 291,019 | 0 | 46,901 | 1,352,080 |
| Rutul Shah | Chief Operating Officer | 2024 | 452,116 | 0 | 305,249 | 0 | 46,334 | 1,407,544 |
| Helen Sabzevari | Chief Executive Officer | 2024 | 1,000,000 | 0 | 2,432,249 | 0 | 20,132 | 5,431,895 |
| Harry Thomasian Jr. | Chief Financial Officer | 2024 | 486,500 | 0 | 331,250 | 0 | 35,752 | 1,402,452 |
| Phil Tennant | Chief Commercial Officer | 2024 | 215,769 | 0 | 28,250 | 0 | 21,658 | 518,337 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 99 |
| 2023 | 134 |
| 2022 | 209 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 0 | 0 | 26,909,000 |
| Cost Of Revenue | 4,267,000 | 6,119,000 | 6,339,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 53,070,000 | 48,614,000 | 47,170,000 |
| General And Administrative Expenses | 41,293,000 | 40,415,000 | 48,006,000 |
| Operating Expenses | 138,954,000 | 105,983,000 | 102,635,000 |
| Operating Income | -135,029,000 | -99,758,000 | -75,726,000 |
| Net Income | -126,235,000 | -95,904,000 | 28,317,000 |
| Earnings Per Share Basic | -0.47 | -0.39 | 0.14 |
| Earnings Per Share Diluted | -0.47 | -0.39 | 0.14 |
| Weighted Average Shares Outstanding Basic | 267,727,426 | 244,536,221 | 200,360,821 |
| Weighted Average Shares Outstanding Diluted | 267,727,426 | 244,536,221 | 200,360,821 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 29,517,000 | 7,578,000 | 4,858,000 |
| Marketable Securities Current | 68,393,000 | 55,277,000 | 51,092,000 |
| Accounts Receivable | 926,000 | 902,000 | 959,000 |
| Inventories | — | — | 287,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 102,414,000 | 68,755,000 | 118,159,000 |
| Marketable Securities Non Current | — | — | 0 |
| Property Plant And Equipment | 13,831,000 | 7,111,000 | 7,329,000 |
| Other Assets Non Current | 371,000 | 767,000 | 1,025,000 |
| Total Assets Non Current | 42,852,000 | 82,288,000 | 97,818,000 |
| Total Assets | 145,266,000 | 151,043,000 | 215,977,000 |
| Accounts Payable | 3,531,000 | 1,726,000 | 4,068,000 |
| Deferred Revenue | 589,000 | 509,000 | 25,000 |
| Short Term Debt | — | 0 | 43,219,000 |
| Other Liabilities Current | — | — | — |
| Total Liabilities Current | 21,518,000 | 22,985,000 | 78,645,000 |
| Long Term Debt | — | — | 43,219,000 |
| Other Liabilities Non Current | — | — | — |
| Total Liabilities Non Current | 57,017,000 | 9,560,000 | 11,073,000 |
| Total Liabilities | 78,535,000 | 32,545,000 | 89,718,000 |
| Common Stock | 0 | 0 | 0 |
| Retained Earnings | -2,090,706,000 | -1,964,471,000 | -1,868,567,000 |
| Accumulated Other Comprehensive Income | 12,000 | -1,947,000 | -3,488,000 |
| Total Shareholders Equity | 38,513,000 | 118,498,000 | 126,259,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 4,526,000 | 6,668,000 | 10,765,000 |
| Share Based Compensation Expense | 9,471,000 | 9,888,000 | 10,206,000 |
| Other Non Cash Income Expense | 0 | -2,000 | -106,000 |
| Change In Accounts Receivable | 24,000 | -76,000 | 2,229,000 |
| Change In Inventories | — | — | -2,341,000 |
| Change In Non Trade Receivables | -438,000 | -12,153,000 | 11,338,000 |
| Change In Other Assets | -120,000 | -129,000 | 101,000 |
| Change In Accounts Payable | 1,549,000 | -2,421,000 | 379,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | -68,173,000 | -66,930,000 | -65,045,000 |
| Purchases Of Marketable Securities | 187,206,000 | 185,026,000 | 0 |
| Sales Of Marketable Securities | 175,016,000 | 183,377,000 | 68,441,000 |
| Acquisition Of Property Plant And Equipment | 8,584,000 | 1,536,000 | 4,924,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -20,714,000 | -3,087,000 | 226,417,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | 31,237,000 | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | 0 | 43,219,000 | 154,705,000 |
| Other Financing Activities | — | — | — |
| Cash From Financing Activities | 110,583,000 | 29,589,000 | -155,292,000 |
| Change In Cash | 21,669,000 | -40,748,000 | 5,253,000 |
| Cash At End Of Period | 29,517,000 | 7,578,000 | 4,858,000 |
| Income Taxes Paid | 4,000 | 21,000 | 0 |
| Interest Paid | 7,000 | 1,171,000 | 8,535,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | -0.47 | -0.39 | 0.14 |
| Price To Earnings Ratio | -2.383 | -3.4359 | 10.8571 |
| Earnings Growth Rate | 20.5128 | -378.5714 | -129.7872 |
| Price Earnings To Growth Ratio | -0.1162 | 0.0091 | -0.0837 |
| Book Value Per Share | 0.2492 | 0.4846 | 0.6302 |
| Price To Book Ratio | 4.4935 | 2.7653 | 2.4121 |
| Ebitda | -121,699,000 | -88,747,000 | 45,856,000 |
| Enterprise Value | — | — | 386,128,447.92 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | — | — | 0.6846 |
| Capital Expenditures | 11,246,000 | 6,450,000 | -16,221,000 |
| Free Cash Flow | -79,419,000 | -73,380,000 | -48,824,000 |
| Return On Equity | -3.2777 | -0.8093 | 0.2243 |
| One Year Beta | 1.6578 | 2.1757 | 1.7571 |
| Three Year Beta | 1.8106 | 1.6677 | 1.5533 |
| Five Year Beta | 1.6063 | 1.6123 | 1.5594 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| KIRK RANDAL J | Director, 10% owner | 2025-09-30 | 1,809,667 | D | 14,597,161 |
| KINDLER JEFFREY B | Director | 2025-09-30 | 106,837 | D | 346,070 |
| Tennant Phil | Chief Commercial Officer | 2025-09-29 | 6,000 | A | 65,031 |
| KINDLER JEFFREY B | Director | 2025-09-29 | 67,523 | D | 452,907 |
| Thomasian Harry Jr. | Chief Financial Officer | 2025-09-26 | 2,932 | A | 468,626 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| STRS OHIO | 2025-09-30 | 165,816 | 50,400 | 3.29 |
| Patient Capital Management, LLC | 2025-09-30 | 87,056,189 | 26,460,848 | 3.29 |
| AMALGAMATED BANK | 2025-09-30 | 15,000 | 4,621 | 3.2461 |
| EASTERN BANK | 2025-09-30 | 10 | 3 | 3.3333 |
| Janney Montgomery Scott LLC | 2025-09-30 | 99,000 | 30,013 | 3.2986 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Small Cap II Fund - Class A | SECAX | 55,849 | 251,878.99 | 0.1033 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT SMALL CAP FUND - CLASS A | SLPAX | 27,097 | 122,207.47 | 0.0645 |
| SEI INSTITUTIONAL INVESTMENTS TRUST | 2025-08-31 | SIIT Extended Market Index Fund - Class A | SMXAX | 21,300 | 96,063 | 0.0079 |
| Northern Lights Fund Trust IV | 2025-08-31 | Inspire Small/Mid Cap ETF | ISMD | 283,247 | 1,277,443.97 | 0.5808 |
| PROSHARES TRUST | 2025-08-31 | ProShares Ultra Russell2000 | UWM | 15,183 | 68,475.33 | 0.0187 |